Lynk Pharmaceuticals Announces NMPA Acceptance of New Drug Application for Zemprocitinib in the Treatment of Rheumatoid Arthritis
SHANGHAI and HANGZHOU, China and BOSTON, Nov. 5, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, announced that the New Drug Application (NDA) for its core...
Covered in this story
Call it yourself
No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NOV →Dalsna Finance is currently tracking 101 stories mentioning NOV, the earliest published 7 Oct 2025.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.